167 results on '"Benitez-Ribas, Daniel"'
Search Results
2. CART19-BE-01: A Multicenter Trial of ARI-0001 Cell Therapy in Patients with CD19+ Relapsed/Refractory Malignancies
3. Integrative single-cell multi-omics of CD19-CARposand CARnegT cells suggest drivers of immunotherapy response in B-cell neoplasias
4. Restoring immune tolerance in neuromyelitis optica
5. Restoring immune tolerance in neuromyelitis optica
6. Immune tolerance in multiple sclerosis and neuromyelitis optica with peptide-loaded tolerogenic dendritic cells in a phase 1b trial
7. Development of a Novel Anti-CD19 Chimeric Antigen Receptor: A Paradigm for an Affordable CAR T Cell Production at Academic Institutions
8. 3083 – SINGLE CELL MULTIOMIC ANALYSIS OF CLONAL AND TRANSCRIPTIONAL PROGRAMS OF CD19 CAR T CELLS IN THE IMMUNOTHERAPY RESPONSE
9. P1356: CD84-TARGETED CART-CELL THERAPY: A NOVEL STRATEGY FOR THE TREATMENT OF HAEMATOLOGICAL MALIGNANCIES
10. P1391: VARNIMCABTAGENE AUTOLEUCEL (VAR-CEL) IN RELAPSED/ REFRACTORY CD19+ NON-HODGKIN LYMPHOMA
11. P1394: RITUXIMAB BASED LYMPHODEPLETION MAY INCREASE ENGRAFTMENT AND EFFICACY OF SECOND INFUSIONS OF CART19 CELLS IN B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA.
12. Direct In Vivo Activation of T Cells with Nanosized Immunofilaments Inhibits Tumor Growth and Metastasis
13. Phase II randomised trial of autologous tumour lysate dendritic cell plus best supportive care compared with best supportive care in pre-treated advanced colorectal cancer patients
14. Commensal-Specific CD4+ Cells From Patients With Crohn’s Disease Have a T-Helper 17 Inflammatory Profile
15. Supplementary Table 1 from Natural Human Plasmacytoid Dendritic Cells Induce Antigen-Specific T-Cell Responses in Melanoma Patients
16. Supplementary Figure 2 from Natural Human Plasmacytoid Dendritic Cells Induce Antigen-Specific T-Cell Responses in Melanoma Patients
17. Supplementary Figure 1 from Natural Human Plasmacytoid Dendritic Cells Induce Antigen-Specific T-Cell Responses in Melanoma Patients
18. Supplementary Table 2 from Natural Human Plasmacytoid Dendritic Cells Induce Antigen-Specific T-Cell Responses in Melanoma Patients
19. In vivo tracking and immunological properties of pulsed porcine monocyte-derived dendritic cells
20. Biologic Therapy of Ulcerative Colitis: Natalizumab, Vedolizumab, Etrolizumab (rhuMAb β7)
21. Post-mortem neuropathologic examination of a 5-case series of CAR T-cell treated patients
22. Post-mortem neuropathologic examination of a 6-case series of CAR T-cell treated patients
23. Immunofilaments Provide a Nanoscale Platform for In Vivo T Cell Expansion and Cancer Immunotherapy
24. A Phase I-II multicenter trial with Avelumab plus autologous dendritic cell vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer patients. GEMCAD 1602 study
25. Dendritic cells: Nearly 40 years later…
26. Identification of immunosuppressive factors in retinoblastoma cell secretomes and aqueous humor from patients
27. Prophylactic vaccines mimic synthetic CpG oligonucleotides in their ability to modulate immune responses
28. Células dendríticas: ¿un nuevo horizonte en la terapia celular de la enfermedad inflamatoria intestinal?
29. Analysis of HLDA9 mAbs on plasmacytoid dendritic cells
30. Commonly used prophylactic vaccines as an alternative for synthetically produced TLR ligands to mature monocyte-derived dendritic cells
31. First report of CART treatment in AL amyloidosis and relapsed/refractory multiple myeloma
32. Factors associated with the clinical outcome of patients with relapsed/refractory CD19+ acute lymphoblastic leukemia treated with ARI-0001 CART19-cell therapy
33. Vaccines for Non-Viral Cancer Prevention
34. Impact of Salvage and Bridging Therapy in Adult Patients with Refractory B-Cell Acute Lymphoblastic Leukemia (B-ALL) Referred for Anti-CD19 CAR T-Cell Therapy: An Intention to Treat Analysis
35. Varnimcabtagene Autoleucel (ARI-0001) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) and Richter Transformation (RT)
36. Targeting DCIR on human plasmacytoid dendritic cells results in antigen presentation and inhibits IFN-α production
37. Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy
38. Polyinosinic polycytidylic acid prevents efficient antigen expression after mRNA electroporation of clinical grade dendritic cells
39. Maturation of monocyte-derived dendritic cells with Toll-like receptor 3 and 7/8 ligands combined with prostaglandin E2 results in high interleukin-12 production and cell migration
40. CART19-BE-01: A EUROPEAN ACADEMIC TRIAL ON THE ADMINISTRATION OF ARI-0001 CELLS IN PATIENTS WITH CD19+LYMPHOPROLIFERATIVE DISORDERS
41. Mesenchymal stem cell therapy of Crohnʼs disease: are the far-away hills getting closer?
42. IMMU-22. PHASE IB IMMUNOTHERAPY CLINICAL TRIAL WITH THE USE OF AUTOLOGOUS DENDRITIC CELLS PULSED WITH AN ALLOGENIC TUMORAL CELL LINES LYSATE IN PATIENTS WITH NEWLY DIAGNOSED DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)
43. Correlative Biological Studies Related to the Response, Peak and Persistence of ARI0002h, an Academic BCMA-Directed CAR-T Cell, with Fractionated Initial Infusion and Booster Dose for Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)
44. P-008: First report of a patient with systemic light chain amyloidosis in the course of Multiple Myeloma treated with CAR T cells directed against B-cell maturation antigen
45. Corrigendum: Immune Response Generated With the Administration of Autologous Dendritic Cells Pulsed With an Allogenic Tumoral Cell-Lines Lysate in Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma
46. DIPG-18. IMMUNE RESPONSE GENERATED WITH THE USE OF AUTOLOGOUS DENDRITIC CELLS PULSED WITH AN ALLOGENIC TUMORAL CELL LINES LYSATE IN PATIENTS WITH NEWLY DIAGNOSED DIPG
47. Tolerogenic Dendritic Cells as a Promising Antigen-Specific Therapy in the Treatment of Multiple Sclerosis and Neuromyelitis Optica From Preclinical to Clinical Trials
48. Immune Response Generated With the Administration of Autologous Dendritic Cells Pulsed With an Allogenic Tumoral Cell-Lines Lysate in Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma
49. Restoring immune tolerance in neuromyelitis optica: Part II
50. Restoring immune tolerance in neuromyelitis optica: Part I
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.